Summary Zafgen Inc (Zafgen) is a biopharmaceutical company that develops therapeutics for patients suffering from obesity and related disorders. The company’s product beloranib is a novel obesity therapy provided for obesity patients. It concentrates on targeting fat tissue to treat obesity. The company’s pipeline products include, beloranib, ZGN-839 and MetAP2i. Zafgen’s obesity treatments include weight loss programs, over-the-counter medications and exercise regimens. It provides services such as safely manipulating and shrinking the supply of blood to fat tissue leading to the loss of fat. The company operates through academic institutions, other companies and contract research organizations for the development of therapeutic drugs against obesity. Zafgen is headquartered in Boston, Massachusetts, the US. Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed... Research Beam Model: Research Beam Product ID: 1995136 250 USD New
Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 37
  • Publisher : GlobalData
 
 
 
Summary

Zafgen Inc (Zafgen) is a biopharmaceutical company that develops therapeutics for patients suffering from obesity and related disorders. The company’s product beloranib is a novel obesity therapy provided for obesity patients. It concentrates on targeting fat tissue to treat obesity. The company’s pipeline products include, beloranib, ZGN-839 and MetAP2i. Zafgen’s obesity treatments include weight loss programs, over-the-counter medications and exercise regimens. It provides services such as safely manipulating and shrinking the supply of blood to fat tissue leading to the loss of fat. The company operates through academic institutions, other companies and contract research organizations for the development of therapeutic drugs against obesity. Zafgen is headquartered in Boston, Massachusetts, the US.

Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Zafgen Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Zafgen Raises US$45 Million In Series E Financing Round 10
Zafgen Raises US$21 Million In Series D Financing 11
Zafgen Raises US$3 Million In Venture Financing 12
Zafgen Secures US$33 Million In Series C Financing 13
Partnerships 14
ZappRx Enters into Agreement with Zafgen 14
Equity Offering 15
Zafgen Raises USD138 Million in Public Offering of Shares 15
Zafgen Raises USD110.4 Million in IPO 17
Zafgen Inc - Key Competitors 19
Zafgen Inc - Key Employees 20
Zafgen Inc - Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Aug 08, 2017: Zafgen Reports Second Quarter 2017 Financial Results 22
May 09, 2017: Zafgen Reports First Quarter 2017 Financial Results 24
Mar 09, 2017: Zafgen Reports Fourth Quarter And Full Year 2016 Financial Results 26
Nov 09, 2016: Zafgen Reports Third Quarter 2016 Financial Results 27
Aug 04, 2016: Zafgen Reports Second Quarter 2016 Financial Results 29
May 10, 2016: Zafgen Reports First Quarter 2016 Financial Results 31
Mar 09, 2016: Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results 32
Corporate Communications 34
Mar 08, 2016: Zafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors 34
Clinical Trials 35
Jul 19, 2016: Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 35
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Zafgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Zafgen Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Zafgen Raises US$45 Million In Series E Financing Round 10
Zafgen Raises US$21 Million In Series D Financing 11
Zafgen Raises US$3 Million In Venture Financing 12
Zafgen Secures US$33 Million In Series C Financing 13
ZappRx Enters into Agreement with Zafgen 14
Zafgen Raises USD138 Million in Public Offering of Shares 15
Zafgen Raises USD110.4 Million in IPO 17
Zafgen Inc, Key Competitors 19
Zafgen Inc, Key Employees 20
List of Figures
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter